Immunovant, Inc. — Form 10-Q Summary
Business context and reporting period
Clinical-stage biopharmaceutical company developing batoclimab (IMVT-1401), a fully human anti-FcRn monoclonal antibody for autoimmune diseases. The filing covers the three and six months ended September 30, 2021, Immunovant’s fiscal second quarter and first six months of fiscal 2022. The financial statements are unaudited and prepared under U.S. GAAP.
Financial performance and liquidity
| Metric | Three months ended September 30 | Six months ended September 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $21.4 million | $40.1 million |
| General and administrative expense | $16.3 million | $27.5 million |
| Total operating expenses | $37.7 million | $67.5 million |
| Net loss | $37.7 million | $68.2 million |
| Net loss per share | $0.35 | $0.66 |
| Cash used in operating activities | Not separately presented | $41.3 million |
There is no meaningful revenue or profit margin because the company has no approved products and has never generated product revenue. Accumulated deficit was $266.8 million at September 30, 2021. Cash was $559.0 million, compared with $400.1 million at March 31, 2021. Total assets were $566.7 million and total liabilities were $30.3 million. The filing reports no material debt or credit facilities.
Financing activities provided $200.1 million during the first six months, principally from a $200.0 million investment by Roivant Sciences Ltd. Operating cash use increased from $38.0 million in the comparable 2020 period. Management expects existing cash to fund operating expenses and capital expenditures for at least the next 12 months, but states that current funds will not be sufficient to complete all development and commercialization activities.
Material changes versus the prior comparable period
- Quarterly R&D expense increased $9.4 million, or approximately 78%, to $21.4 million; six-month R&D expense increased $11.2 million, or approximately 39%, to $40.1 million.
- Quarterly G&A expense increased $7.3 million, or approximately 81%, to $16.3 million; the increase included approximately $5.0 million of accrued financial advisory fees related to the Roivant transaction and other potential transactions.
- Quarterly net loss increased $16.9 million to $37.7 million; six-month net loss increased $20.7 million to $68.2 million.
- On August 2, 2021, Immunovant issued 17.0 million common shares to Roivant at $11.75 per share for $200.0 million of net proceeds. Common shares outstanding increased to approximately 115.0 million at September 30, 2021 from approximately 98.0 million at March 31, 2021.
- Stock-based compensation increased to $7.7 million in the quarter and $11.5 million in the first six months, versus $3.3 million and $7.2 million, respectively, in the prior-year periods.
- The company repriced 2.5 million stock options to an exercise price of $8.62 per share, resulting in $2.6 million of incremental stock-based compensation expense.
Guidance, outlook, risks and unusual items
- Clinical dosing was voluntarily paused in February 2021 after dose-dependent increases in total cholesterol and LDL cholesterol and reductions in albumin were observed. No major adverse cardiovascular events had been reported in the trials as of the filing.
- Management intends to resume clinical studies after selecting dosing regimens and risk-mitigation procedures intended to preserve IgG reduction while limiting lipid and albumin effects.
- Management expected an FDA meeting in the fourth quarter of calendar 2021 regarding modifications to the pivotal myasthenia gravis Phase 3 study and planned to initiate that study in early 2022, contingent on FDA feedback.
- The ASCEND WAIHA study was closed to support planning for a randomized controlled study, and a thyroid eye disease trial was expected to be re-initiated only after regulatory alignment. These timelines remain contingent and are not assured.
- Batoclimab is the company’s sole product candidate. Regulatory approval, efficacy, safety, manufacturing, enrollment and commercialization remain uncertain, and the company expects significant additional losses.
- The HanAll license includes potential milestone payments of up to $442.5 million, reimbursement of up to $20.0 million for certain research and development costs, and tiered royalties ranging from the mid-single digits to mid-teens on net sales.
- A putative securities class action filed in February 2021 alleges misleading statements concerning batoclimab’s safety. The company has not accrued a liability because potential losses cannot currently be reasonably estimated and an unfavorable outcome is not determined to be probable.
- Roivant beneficially owned approximately 63.8% of voting power as of November 5, 2021, making Immunovant a controlled company and creating potential conflicts with minority stockholders.
- COVID-19 had not caused material financial effects through the filing date, but previously slowed trial enrollment and could affect future enrollment, supply chains, operations and access to capital.
Important facts for investors to verify
- Whether batoclimab clinical trials actually resumed, on what dosing schedule, and whether lipid and albumin abnormalities remain manageable.
- FDA feedback and the timing, design and initiation of the planned myasthenia gravis Phase 3 trial.
- Updated cash-burn rates, projected runway and the timing and terms of any additional financing.
- Potential dilution and governance implications of Roivant’s controlling ownership and related-party arrangements.
- Remaining contingent obligations under the HanAll Agreement and the status of the securities class action.
- Whether future clinical data demonstrate sufficient efficacy and a favorable long-term benefit-risk profile to support regulatory approval.